AMENDMENTS TO THE CLAIMS:

Claims 1-4 (canceled)

5. (New) A 3-deoxy-D-myo-inositol analog having the formula (I):



(I)

wherein X is O or CH_2; R^1 and R^2 are individually, (C_1 -C_{25}) alkyl, (C_6 –C_{10}) aryl, (C_3 -C_8) cycloalkyl, (C_2 -C_{22}) alkenyl, (C_5 -C_8) cycloalkenyl, (C_7 -C_{32}) aralkyl, (C_7 -C_{32}) alkylaryl, (C_6 – C_{32}) aralkenyl, (C_9 -C_{32}) alkenylaryl or $C(O)R^3$; and R^3 is (C_1 -C_{25}) alkyl, (C_6 -C_{10}) aryl, (C_3 -C_8) cycloalkyl, (C_2 -C_{22}) alkenyl, (C_5 -C_8) cycloalkenyl, (C_7-C_{32}) aralkyl, (C_7 –C_{32}) alkylaryl, (C_9 - C_{32}) aralkenyl or (C_9 -C_{32}) alkenylaryl, with the proviso that when X is O, R^3 is not (C_{15}) alkyl; R^4 and R^5 are individually hydrogen or a phosphate group; or when R^4 or R^5 is not hydrogen, a pharmaceutically acceptable salt thereof.

6. (New) The 3-deoxy-D-myo-inositol analog of claim 5, wherein X is O.

7. (New) The 3-deoxy-D-myo-inositol analog of claim 6, wherein R^1 is methyl.

8. (New) The 3-deoxy-D-myo-inositol analog of claim 6, wherein R^2 is octadecyl.

9. (New) The 3-deoxy-D-myo-inositol analog of claim 5, wherein X is CH_2.

10. (New) The 3-deoxy-D-myo-inositol analog of claim 9, wherein O—R^1 and/or O—R^2 is palmitoyl.

11. (New) A method of inhibiting cell growth in a subject in need of such inhibition comprising administering to a subject an effective amount of a 3-deoxy-D-myo-inositol analog according to claim 5.

12. (New) The method of claim 11, wherein the compound is 1-O-octadecyl-2-O-methyl-sn-glycero-3-phospho-1D-3-deoxy-myo-inositol.

13. (New) The method of claim 12, wherein 1-O-octadecyl-2-O-methyl-sn-glycero-3-phospho-1D-3-deoxy-myo-inositol is administered to a subject in a daily dose of between 0.1 and 500 mg for each kilogram of the subject's weight.

14. (New) The method of claim 13, wherein 1-O-octadecyl-2-O-methyl-sn-glycero-3-phospho-1D-3-deoxy-myo-inositol is administered to a subject in a daily dose of about 50-100 mg for each kilogram of the subject's weight.

15. (New) The method of claim 11, wherein said compound inhibits PtdIns-3-kinase signaling.

16. (New) The method of claim 15, wherein inhibiting PtdIns-3-kinase signaling comprises inhibiting a src-homology 2 domain of a p85 regulatory subunit of PtdIns-3-kinase.

17. (New) The method of claim 11, wherein inhibiting cell growth comprises inhibiting the activity of a PH domain in a PH domain containing enzyme.

18. (New) The method of claim 17, wherein the PH domain activates the enzyme PKC-ζ and/or PKC-γ.

19. (New) The method of claim 11, wherein inhibiting cell growth comprises promoting the activity of a PH domain in a PH domain containing enzyme.

20. (New) The method of claim 19, wherein the PH domain activates the enzyme Akt.

21. (New) A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to claim 5, and a pharmaceutically acceptable carrier.

22. (New) The composition of claim 21, which is suitable for administration via injection, orally, transdermally, intranasally, intraocularly, or rectally.